SK Biopharmaceuticals Co., Ltd. (KRX:326030)

SK Biopharmaceuticals Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	266,946	322,807	239,700	104,060	225,922	59,333
Short-Term Investments	1,749	1,682	1,418	201,394	108,417	328,657
Cash & Short-Term Investments	268,695	324,489	241,118	305,454	334,339	387,991
Cash Growth	-7.68%	34.58%	-21.06%	-8.64%	-13.83%	371.01%
Accounts Receivable	174,823	173,819	111,001	63,506	55,883	8,563
Other Receivables	475.07	433.79	2,641	2,945	1,477	3,990
Receivables	175,298	174,253	113,642	66,451	57,360	12,553
Inventory	115,332	111,679	102,525	90,920	51,933	23,040
Prepaid Expenses	40,431	30,125	25,898	18,734	20,964	10,920
Other Current Assets	7,197	10,825	5,538	6,366	6,622	99.95
Total Current Assets	606,952	651,371	488,722	487,925	471,219	434,603
Property, Plant & Equipment	57,803	43,932	47,753	20,350	22,938	24,233
Long-Term Investments	87,317	91,439	104,091	99,959	107,665	6,849
Goodwill	1,687	1,691	3,392	-	-	-
Other Intangible Assets	7,708	8,875	14,542	17,181	18,900	19,695
Long-Term Deferred Tax Assets	208,265	206,400	44,723	29,641	18,919	11,837
Long-Term Deferred Charges	21,939	21,963	9,090	-	-	-
Other Long-Term Assets	10,297	11,059	10,771	9,107	3,985	3,025
Total Assets	1,002,035	1,036,811	723,171	664,241	643,652	500,241
Accounts Payable	14,088	3,403	2,346	23,106	16,931	8,954
Accrued Expenses	69,842	79,653	71,331	55,035	64,776	36,543
Short-Term Debt	50,000	50,000	50,000	-	-	-
Current Portion of Long-Term Debt	25,000	100,715	-0	-	-	-
Current Portion of Leases	7,377	7,091	7,061	5,644	5,481	4,906
Current Income Taxes Payable	460.62	451.82	88.78	208.36	1,997	-
Other Current Liabilities	163,465	154,962	110,792	79,079	59,120	20,193
Total Current Liabilities	330,232	396,276	241,619	163,073	148,306	70,595
Long-Term Debt	-	-	94,484	143,722	-	-
Long-Term Leases	42,283	26,676	26,505	6,530	10,256	13,572
Long-Term Deferred Tax Liabilities	-	-	1,909	-	-	-
Other Long-Term Liabilities	38,045	39,874	37,703	34,356	40,850	36,915
Total Liabilities	410,561	462,827	402,219	347,681	199,465	121,175
Common Stock	39,157	39,157	39,157	39,157	39,157	39,157
Additional Paid-In Capital	1,084,848	1,084,848	1,084,848	1,084,848	1,084,848	1,084,848
Retained Earnings	-597,911	-621,532	-861,561	-827,555	-689,141	-746,951
Comprehensive Income & Other	41,438	43,800	21,243	20,112	9,325	2,013
Total Common Equity	567,531	546,273	283,686	316,560	444,187	379,067
Minority Interest	23,942	27,711	37,265	-	-	-
Shareholders' Equity	591,474	573,984	320,951	316,560	444,187	379,067
Total Liabilities & Equity	1,002,035	1,036,811	723,171	664,241	643,652	500,241
Total Debt	124,660	184,482	178,050	155,896	15,738	18,478
Net Cash (Debt)	144,034	140,007	63,068	149,558	318,602	369,513
Net Cash Growth	67.23%	121.99%	-57.83%	-53.06%	-13.78%	-
Net Cash Per Share	1839.21	1787.78	805.33	1909.74	4068.30	5148.87
Filing Date Shares Outstanding	78.31	78.31	78.31	78.31	78.31	78.31
Total Common Shares Outstanding	78.31	78.31	78.31	78.31	78.31	78.31
Working Capital	276,720	255,095	247,104	324,852	322,914	364,007
Book Value Per Share	7246.94	6975.49	3622.46	4042.23	5671.93	4840.39
Tangible Book Value	558,137	535,708	265,752	299,380	425,288	359,371
Tangible Book Value Per Share	7126.98	6840.58	3393.45	3822.85	5430.60	4588.90
Buildings	-	-	-	-	-	159.12
Machinery	32,147	32,717	30,611	21,078	19,165	18,238
Construction In Progress	70.12	201.95	236.84	1,643	1,276	375.64

Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.